Personalized radiation therapy (PRT) for lung cancer

JianYue Jin, Feng Ming Kong

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages175-202
Number of pages28
DOIs
StatePublished - Oct 1 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume890
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Radiotherapy
Lung Neoplasms
Tumors
Biomarkers
Histology
Fractionation
Appointments and Schedules
Therapeutics
Neoplasms
Metabolomics
Genomics
Tumor Burden
MicroRNAs
Proteomics
Multicenter Studies
Cost-Benefit Analysis
Blood
Cytokines

Keywords

  • Adaptive radiation therapy
  • Biomarkers
  • Lung cancer
  • Personalized radiation therapy
  • Radiomics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jin, J., & Kong, F. M. (2016). Personalized radiation therapy (PRT) for lung cancer. In Advances in Experimental Medicine and Biology (pp. 175-202). (Advances in Experimental Medicine and Biology; Vol. 890). Springer New York LLC. https://doi.org/10.1007/978-3-319-24932-2_10

Personalized radiation therapy (PRT) for lung cancer. / Jin, JianYue; Kong, Feng Ming.

Advances in Experimental Medicine and Biology. Springer New York LLC, 2016. p. 175-202 (Advances in Experimental Medicine and Biology; Vol. 890).

Research output: Chapter in Book/Report/Conference proceedingChapter

Jin, J & Kong, FM 2016, Personalized radiation therapy (PRT) for lung cancer. in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 890, Springer New York LLC, pp. 175-202. https://doi.org/10.1007/978-3-319-24932-2_10
Jin J, Kong FM. Personalized radiation therapy (PRT) for lung cancer. In Advances in Experimental Medicine and Biology. Springer New York LLC. 2016. p. 175-202. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-24932-2_10
Jin, JianYue ; Kong, Feng Ming. / Personalized radiation therapy (PRT) for lung cancer. Advances in Experimental Medicine and Biology. Springer New York LLC, 2016. pp. 175-202 (Advances in Experimental Medicine and Biology).
@inbook{99dd820aa4fc429b93c892681daff567,
title = "Personalized radiation therapy (PRT) for lung cancer",
abstract = "This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.",
keywords = "Adaptive radiation therapy, Biomarkers, Lung cancer, Personalized radiation therapy, Radiomics",
author = "JianYue Jin and Kong, {Feng Ming}",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/978-3-319-24932-2_10",
language = "English (US)",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "175--202",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Personalized radiation therapy (PRT) for lung cancer

AU - Jin, JianYue

AU - Kong, Feng Ming

PY - 2016/10/1

Y1 - 2016/10/1

N2 - This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.

AB - This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.

KW - Adaptive radiation therapy

KW - Biomarkers

KW - Lung cancer

KW - Personalized radiation therapy

KW - Radiomics

UR - http://www.scopus.com/inward/record.url?scp=84951875229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951875229&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-24932-2_10

DO - 10.1007/978-3-319-24932-2_10

M3 - Chapter

C2 - 26703805

AN - SCOPUS:84951875229

T3 - Advances in Experimental Medicine and Biology

SP - 175

EP - 202

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -